Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 16.98%15.13B | 0.72%12.93B | 4.73%4.01B | 15.31%3.13B | -8.66%2.86B | -7.31%2.94B | 3.87%12.84B | -4.21%3.83B | -14.21%2.71B | 18.61%3.13B |
| Cost of revenue | 22.21%11.82B | -1.21%9.67B | -4.12%2.87B | 5.64%2.32B | -0.17%2.36B | -5.15%2.12B | -2.15%9.79B | -11.02%2.99B | -10.06%2.2B | 11.55%2.37B |
| Gross profit | 1.44%3.31B | 6.96%3.26B | 36.60%1.14B | 56.53%803M | -34.95%495M | -12.58%820M | 29.37%3.05B | 31.65%836M | -28.35%513M | 47.77%761M |
| Operating expense | -2.11%2.09B | -0.74%2.13B | 3.71%503M | 13.76%554M | -12.83%564M | -3.40%511M | 10.78%2.15B | -18.90%485M | -5.62%487M | 61.75%647M |
| Staff costs | -1.34%516M | -6.10%523M | -1.84%160M | 3.08%134M | -20.71%111M | -4.84%118M | 7.53%557M | 5.84%163M | -0.76%130M | 26.13%140M |
| Selling and administrative expenses | 2.51%245M | -19.53%239M | ---- | ---- | ---- | ---- | -30.12%297M | ---- | ---- | ---- |
| -Selling and marketing expense | 2.51%245M | -19.53%239M | ---- | ---- | ---- | ---- | -30.12%297M | ---- | ---- | ---- |
| Research and development costs | -13.15%555M | 8.49%639M | 23.08%144M | 60.82%156M | -8.98%223M | -10.77%116M | 56.23%589M | -34.27%117M | -3.00%97M | 512.50%245M |
| Depreciation and amortization | 8.57%76M | 18.64%70M | ---- | ---- | ---- | ---- | 43.90%59M | ---- | ---- | ---- |
| -Depreciation | 8.57%76M | 18.64%70M | ---- | ---- | ---- | ---- | 43.90%59M | ---- | ---- | ---- |
| Other operating expenses | 5.14%695M | 2.32%661M | 27.15%-110M | 1.54%264M | -12.21%230M | 0.73%277M | 11.76%646M | 24.50%-151M | -8.77%260M | 5.22%262M |
| Operating profit | 8.16%1.22B | 25.33%1.13B | 82.05%639M | 857.69%249M | -160.53%-69M | -24.45%309M | 115.83%900M | 848.65%351M | -87.00%26M | -0.87%114M |
| Net non-operating interest income (expenses) | -53.06%-75M | 2.00%-49M | 27.78%-13M | 0.00%-11M | -20.00%-12M | -18.18%-13M | 0.00%-50M | -38.46%-18M | 8.33%-11M | 16.67%-10M |
| Non-operating interest income | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Non-operating interest expense | 53.06%75M | -2.00%49M | -27.78%13M | 0.00%11M | 20.00%12M | 18.18%13M | 0.00%50M | 38.46%18M | -8.33%11M | -16.67%10M |
| Net investment income | -49.06%27M | -18.46%53M | 200.00%12M | 450.00%11M | -109.09%-1M | -35.42%31M | 6.56%65M | -83.33%4M | -88.89%2M | 266.67%11M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 196.08%49M | -264.52%-51M | 31M | |||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 61.49%-67M | -248.00%-174M | -1,457.14%-109M | 20.00%-8M | 27.78%-13M | -193.33%-44M | 53.27%-50M | 82.93%-7M | -233.33%-10M | 58.14%-18M |
| Less:Other special charges | -61.49%67M | 248.00%174M | 1,457.14%109M | -20.00%8M | -27.78%13M | 193.33%44M | -53.27%50M | -82.93%7M | 233.33%10M | -58.14%18M |
| Other non-operating income (expenses) | -3,000.00%-29M | 100.40%1M | 130.77%8M | 93.22%-12M | 0 | 109.80%5M | -837.04%-253M | -333.33%-26M | -453.13%-177M | -80.00%1M |
| Income before tax | 24.20%1.12B | 41.19%905M | 45.51%486M | 234.32%227M | -196.00%-96M | -23.40%288M | 121.80%641M | 33,500.00%334M | -198.83%-169M | 49.25%100M |
| Income tax | 76.74%228M | 53.57%129M | 17.86%66M | 171.19%42M | -234.62%-35M | -8.20%56M | 104.88%84M | 269.70%56M | -240.48%-59M | 44.44%26M |
| Net income | 15.46%896M | 39.57%776M | 51.08%420M | 269.09%186M | -183.78%-62M | -26.11%232M | 124.19%556M | 768.75%278M | -184.62%-110M | 51.02%74M |
| Net income continuous operations | 15.46%896M | 39.32%776M | 51.08%420M | 268.18%185M | -182.43%-61M | -26.35%232M | 124.60%557M | 768.75%278M | -185.27%-110M | 51.02%74M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 15.46%896M | 39.57%776M | 51.08%420M | 269.09%186M | -183.78%-62M | -26.11%232M | 124.19%556M | 768.75%278M | -184.62%-110M | 51.02%74M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 15.46%896M | 39.57%776M | 51.08%420M | 269.09%186M | -183.78%-62M | -26.11%232M | 124.19%556M | 768.75%278M | -184.62%-110M | 51.02%74M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 16.39%41.4 | 39.44%35.57 | 50.78%19.24 | 267.85%8.51 | -184.07%-2.85 | -26.06%10.67 | 124.36%25.51 | 768.03%12.76 | -185.21%-5.07 | 52.70%3.39 |
| Diluted earnings per share | 16.39%41.4 | 39.44%35.57 | 51.04%19.24 | 267.85%8.51 | -184.07%-2.85 | -26.06%10.67 | 124.36%25.51 | 768.78%12.7382 | -185.21%-5.07 | 52.70%3.39 |
| Dividend per share | 12.50%9 | 14.29%8 | 14.29%8 | 0 | 0 | 0 | 75.00%7 | 75.00%7 | 0 | 0 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |